Clinical Performance and Safety of ENDOPACK® DT4-EBMCA in ACL Reconstruction 24 Months Post-surgery : Post-market Clinical Follow-up Study

Inclusion Criteria: * Patient implanted with DT4-EBMCA in Médipôle Garonne for a total or partial rupture of the anterior cruciate ligaments * Patient having answer to IKDC and KOOS pre-operative * Patient having received information and signed informed consent Exclusion Criteria: * Patients who refuse to participate * Patients unable to understand questionnaires * Patients who, at the time of surgery, present the contraindications and Factors likely to jeopardize the success of the implant contained in the IFU : * Acute or chronic, local or systemic infections; * Severe muscular, neurological or vascular impairments affecting the extremity concerned; * Bone destruction or poor bone quality that may affect device stability; * Any concomitant condition that may affect device function; * Patients with sensitivity to device material that may cause allergic reactions. * Severe osteoporosis; * Significant deformity, congenital dislocation; * Local bone tumours; * Systemic or metabolic disorders; * Infectious diseases; * Substance abuse and/or tendencies to abuse drugs or medication; * Obesity; * Unsupervised intense physical activity.